Abstract
No public abstract is available from the verified source records.
Estella Bastian, Lia Bizuneh, Erin H. Amerson, Haley B. Naik
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Two phase 3 trials of adalimumab for hidradenitis suppurativa
10.1056/nejmoa1504370 · 2016
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
10.1016/s0140-6736(23)00022-3 · 2023
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
10.1016/s0140-6736(24)00101-6 · 2024
Concurrent anticytokine biologics for the management of severe hidradenitis suppurativa: are they safe and effective?
2018
Dual Blocking of IL17A and IL36R for the treatment of refractory hidradenitis suppurativa: a case report
2025
No additional external references are available.